Showing results (21-30 of 26) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
European Urology Oncology|October 28, 2020
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR ConsortiumYasmin Abu-Ghanem, Thomas Powles, Umberto Capitanio, et al.Oncoimmunology|September 14, 2020
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibitionVictor Cervera-Carrascon, Dafne C A Quixabeira, Joao Manuel Santos, et al.Journal for Immunotherapy of Cancer|August 7, 2021
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoidsFiras Hamdan, Erkko Ylösmäki, Jacopo Chiaro, et al.BJU International|April 1, 2021
Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?Yasmin Abu-Ghanem, Thomas Powles, Umberto Capitanio, et al.Urologic Oncology|September 20, 2022
Recurrence pattern in localized RCC: results from a European multicenter database (RECUR)Giuseppe Fallara, Alessandro Larcher, Saeed Dabestani, et al.European Urology Oncology|August 27, 2025
Urine Glycosaminoglycan Scores for Surveillance of Recurrence in Intermediate- and High-risk Nonmetastatic Clear Cell Renal Cell Carcinoma-An Observational Prospective Multicentre Diagnostic Test Cohort StudySaeed Dabestani, Nessn H Azawi, Riccardo Campi, et al.Pageof 3